Europe Thin Film Drugs Market

Europe Thin Film Drugs Market Size (2024 to 2029)

As per the research report, the size of the Europe Thin Film Drugs market is valued at USD 5.67 billion in 2024 and is expected to reach USD 8.93 billion by 2029 at 9.33% CAGR during the forecast period 2024 to 2029.

The European thin-film drugs market is developing robust business strategies, aiming to influence various users and customers, primarily driving the market. Thin-film drugs are emerged as an alternative to tablets or capsules due to their improved efficacy. The drugs are made from polymers that dissolve quickly when held in the mouth or oral cavity, delivering the drug directly into the body's systemic circulation, especially by sublingual absorption. The bioavailability of a sublingually administered dose is around 35%, with the onset of reaction in 5-10 mins. All these factors increase the popularity of thin film drugs in the pharmaceutical industry.

Oral thin-film drugs provide high patient compliance ease of storage and transport. In addition, they offer precise dosing with the desired effective result. Thus, the thin film drug delivery systems market has been substantially attractive for the past several years. The high level of acceptance and the impressive benefits have further boosted the European thin films drugs market.

Coupled with effective customer-centric strategies will increase the volume of consumers. Furthermore, drivers such as growing demand for efficient drug delivery systems, low cost of manufacturing thin film drugs compared to traditional dosage forms, and increased research to develop new polymeric thin films are predicted to increase the demand for the European market.

In addition, beneficial government initiatives and an increase in the number of pharmaceutical companies are other drivers expected to increase the growth of the Europe thin film drugs market.

However, the European thin film drugs market will be negatively impacted by the high costs of treatment, availability of various alternative drug delivery options, and lack of awareness. In addition, some of the solvents and polymers used in film coating are relatively harmful. Inflammation due to some of the organic solvents used as vehicles for film-forming polymers could present a risk to the patient.

This research report on the Europe Thin Film Drugs Market has been segmented and sub-segmented into the following categories.

Europe Thin Film Drugs Market Analysis By Product

• Oral Thin Film
• Transdermal Thin Film

Europe Thin Film Drugs Market Analysis By Disease Indication

• Schizophrenia, Migraine
• Opioid Dependence
• Nausea and Vomiting

Europe Thin Film Drugs Market Analysis By Distribution Channel

• Hospital Pharmacies
• Drug Store
• Retail Pharmacies
• E-Commerce

Europe Thin Film Drugs Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the German thin film drugs market is anticipated to grow by around 6.2% CAGR during the forecast period. The presence of a large population of geriatric patients with dysphagia and the increase in healthcare spending will help drive the market in Germany in the coming years. In 2015, just over 4.65 million people in Germany were at least 80 years old. Their number will continue to grow over the next decades and reach around 9.97 million by 2050; this corresponds to a population share of about 13%.

The Spain thin film drugs market is expected to be a lucrative market for thin films drugs during the mentioned period. And the France thin film drugs market is leading the market in the improving awareness, production, and distribution of oral thin-film drugs, which will also help the progress of the Europe thin film drugs market. Furthermore, a large population of geriatric patients focuses on providing other drug delivery options, especially for critical drugs, and more clinical trials in laboratories, medical institutes, and research centers in these countries drive the market in the coming years.

The U.K thin film drugs market accounted for over 55% due to owing to the presence of advanced technologies for pharmaceutical research and development, high investment for the discovery of new drug delivery techniques, and the increasing need for effective drug delivery routes and their stability would further stimulate the market for thin film drugs in Europe.

KEY MARKET PLAYERS

Key players operating in the Europe Thin Film Drugs Market profiled in this report are Pfizer Inc, Wolters Kluwer, Solvay, Allergan plc., MonoSol Rx, IntelGenx Corp., ZIM Laboratories Limited, and IntelGenx Corp, Sumitomo Dainippon Pharma Co. Ltd., Indivior Plc, Novartis AG.,